Last edition
News about "Axplora Expands Vizag API Facility After Successfu"
Axplora Expands Vizag API Facility After Successful USFDA Inspections at Indian Sites
The move comes after both of Axplora’s Indian manufacturing sites—Vizag and Chennai—operating under its PharmaZell Business Unit, successfully cleared routine inspections by the US Food and Drug Administration (USFDA) in 2025, receiving a Voluntary Action Indicated (VAI) classification.
Axplora Expands Vizag API Facility After Successfu | 06/08/2025 | By Darshana | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members